KLRC1 and plasma cell myeloma: CRISPR-edited NK cells with reduced expression of the inhibitory KLRC1 locus showed improved anti-myeloma cytolytic activity in vitro, and further study is needed for the clinical utility of ex vivo NK cell engineering in myeloma (92).